Characterization of cardiac disease-associated mutations in RyR2 Ca 2+ and caffeine binding sites
American Journal of Physiology-Cell Physiology · 2026
DOI: 10.1152/ajpcell.00760.2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2026. Verfasst von Venkat R Chirasani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Caffeine, Calcium, Mutation. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, UNC | UNC | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (UNC Lineberger), MUSC | South Carolina Clinical and Translational Research Institute, Medical University of South Carolina (SCTR).
Abstract (Originalsprache)
Cardiac Ca 2+ release channels, type-2 ryanodine receptors (RyR2s) play a pivotal role in cardiac muscle contraction by releasing Ca 2+ from the sarcoplasmic reticulum. Over 200 missense mutations in humans have been reported to be associated with cardiac diseases. Here, we characterize three RyR2 variants, Q3925E, W4646R, and Q4937K. Q3925E and W4646R mutations are in the Ca 2+ and caffeine binding sites, respectively. Our molecular dynamics simulations predicted that the Q4937 residue in the carboxyl terminal domain forms a hydrogen bond interaction with the central domain where the Ca 2+ binding site is located. Three mutant RyR2s were expressed in heterologous cells, and activities of the recombinant mutant RyR2 channels were determined by [ 3 H]ryanodine binding methods. As expected, Q3925E greatly reduced Ca 2+ -dependent activation, and W4646R abolished caffeine activation. Our novel finding is that Q3925E increased inhibitory effects by divalent cations, Ca 2+ and Mg 2+ , resulting in a strong loss-of-function phenotype. Both W4646R and Q4937K increased affinities for Ca 2+ activation, and reduced or unchanged Ca 2+ inhibitions, exhibiting typical gain-of-function phenotypes. Caffeine failed to activate the Q3925E mutant at resting Ca 2+ but restored its activation at ~20 µM Ca 2+ , where Q3925E mutant is at the sub-activated state. Computational predictions of the mutated structures suggested that the Q3925E mutation does not reduce Ca 2+ binding to its site but rearranges domain interface between the central domain involving Ca 2+ binding site and carboxyl terminal domain, which directly interacts with the channel pore. Thus, it is possible that Q3925E-RyR2 mutation alters signal transmission between activating Ca 2+ binding and pore opening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
- R. L. Juliano Structural Bioinformatics Core, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
- Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, South Carolina, United States.
- College of Charleston Honors College, Charleston, South Carolina, United States.
ORCID-Profile: Venkat R Chirasani, Naohiro Yamaguchi
Förderung
- NCI NIH HHS
- UNC | UNC | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (UNC Lineberger)
- MUSC | South Carolina Clinical and Translational Research Institute, Medical University of South Carolina (SCTR)
- HHS | National Institutes of Health (NIH)
- NCATS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Chirasani, V. R., Patwardhan, A., & Yamaguchi, N. (2026). Characterization of cardiac disease-associated mutations in RyR2 Ca 2+ and caffeine binding sites. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00760.2025
Vancouver
Chirasani VR, Patwardhan A, Yamaguchi N. Characterization of cardiac disease-associated mutations in RyR2 Ca 2+ and caffeine binding sites. American Journal of Physiology-Cell Physiology. 2026. doi:10.1152/ajpcell.00760.2025
BibTeX
@article{Chirasani2026,
author = {Chirasani, Venkat R and Patwardhan, Akanksha and Yamaguchi, Naohiro},
title = {Characterization of cardiac disease-associated mutations in RyR2 Ca 2+ and caffeine binding sites},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
doi = {10.1152/ajpcell.00760.2025}
}
EUVIMED